A clinical utility evaluation of dual HIV/Syphilis point-of-care tests in non-clinical settings for screening for HIV and syphilis in men who have sex with men.

Diagnostic evaluation HIV Men who have Sex with Men Non-Governmental Organizations Point-of-care Public health STI testing Syphilis

Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
29 Feb 2024
Historique:
received: 15 09 2022
accepted: 11 01 2024
medline: 1 3 2024
pubmed: 29 2 2024
entrez: 28 2 2024
Statut: epublish

Résumé

Dual point-of-care tests (POCTs) for the simultaneous detection of antibodies to HIV and syphilis have been developed. Since community-based organisations (CBO) are effective providers of HIV and syphilis testing among men who have sex with men (MSM), evaluation of the utility of these dual tests at CBO testing services is a high priority. The aim of this study is to determine the feasibility of performing dual HIV-syphilis POCT testing among both users and providers at these non-clinical sites. This evaluation assessed the utility of two lateral flow immunochromatographic antibody technologies for dual screening for HIV/syphilis among MSM seeking testing in four CBO testing services in Spain, Slovenia, Latvia, and Ukraine. The study's conceptual framework divides the concept of feasibility into two inter-related domains, acceptability, and usability and further breaks it down into six subdomains: learnability, willingness, suitability, satisfaction, efficacy, and effectiveness. The feasibility analysis was performed by calculating the median score in 3 stages (for individual questions, subdomains, and domains), using a summated scores method. The final sample included 844 participants, 60 of which were found to be HIV test positive (7.1%) and 61 (7.2%) positive on testing for syphilis. There was a small difference (1.1%) when comparing the results of the two dual POCTs under evaluation to the tests routinely used at each site. The inter-rater agreement showed a high concordance between two independent readings. The analysis of the feasibility for the users of the services indicated good satisfaction, suitability, and willingness. In addition, among 18 providers the total mean score showed good acceptability and usability, good willingness, easy learnability, high suitability, and good efficacy, but lower satisfaction and effectiveness. The operational characteristics of both dual study POCTs were well evaluated by providers. The introduction of dual HIV and syphilis  POCTs in CBO testing services for screening of MSM is feasible, with a high acceptability and usability both for users and providers. Implementation of dual POCTs for HIV and syphilis in CBO testing services is an opportunity for scaling up integrated HIV/syphilis testing for MSM.

Sections du résumé

BACKGROUND BACKGROUND
Dual point-of-care tests (POCTs) for the simultaneous detection of antibodies to HIV and syphilis have been developed. Since community-based organisations (CBO) are effective providers of HIV and syphilis testing among men who have sex with men (MSM), evaluation of the utility of these dual tests at CBO testing services is a high priority. The aim of this study is to determine the feasibility of performing dual HIV-syphilis POCT testing among both users and providers at these non-clinical sites.
METHODS METHODS
This evaluation assessed the utility of two lateral flow immunochromatographic antibody technologies for dual screening for HIV/syphilis among MSM seeking testing in four CBO testing services in Spain, Slovenia, Latvia, and Ukraine. The study's conceptual framework divides the concept of feasibility into two inter-related domains, acceptability, and usability and further breaks it down into six subdomains: learnability, willingness, suitability, satisfaction, efficacy, and effectiveness. The feasibility analysis was performed by calculating the median score in 3 stages (for individual questions, subdomains, and domains), using a summated scores method.
RESULTS RESULTS
The final sample included 844 participants, 60 of which were found to be HIV test positive (7.1%) and 61 (7.2%) positive on testing for syphilis. There was a small difference (1.1%) when comparing the results of the two dual POCTs under evaluation to the tests routinely used at each site. The inter-rater agreement showed a high concordance between two independent readings. The analysis of the feasibility for the users of the services indicated good satisfaction, suitability, and willingness. In addition, among 18 providers the total mean score showed good acceptability and usability, good willingness, easy learnability, high suitability, and good efficacy, but lower satisfaction and effectiveness. The operational characteristics of both dual study POCTs were well evaluated by providers.
CONCLUSIONS CONCLUSIONS
The introduction of dual HIV and syphilis  POCTs in CBO testing services for screening of MSM is feasible, with a high acceptability and usability both for users and providers. Implementation of dual POCTs for HIV and syphilis in CBO testing services is an opportunity for scaling up integrated HIV/syphilis testing for MSM.

Identifiants

pubmed: 38419023
doi: 10.1186/s12879-024-09017-5
pii: 10.1186/s12879-024-09017-5
pmc: PMC10902924
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

264

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© 2024. The Author(s).

Références

BMJ Open. 2022 Aug 11;12(8):e056887
pubmed: 35953255
PLoS Med. 2013 Aug;10(8):e1001496
pubmed: 23966838
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S187-99
pubmed: 23764635
Int J STD AIDS. 2021 May;32(6):501-509
pubmed: 33533303
AIDS Res Treat. 2013;2013:819593
pubmed: 24527210
BMJ Open. 2014 Dec 15;4(12):e006859
pubmed: 25510889
Sex Transm Infect. 2017 Dec;93(S4):S51-S58
pubmed: 29223963
PLoS One. 2018 Jul 10;13(7):e0198698
pubmed: 29990336
BMC Infect Dis. 2024 Feb 29;24(Suppl 1):194
pubmed: 38418989
Sex Transm Infect. 2017 Dec;93(S4):S81-S88
pubmed: 29223966
Implement Sci. 2012 Jan 23;7:5
pubmed: 22269037
BMJ Open. 2022 Jun 8;12(6):e055275
pubmed: 35676020
Sex Transm Infect. 2020 Aug;96(5):342-347
pubmed: 32241905
J Grad Med Educ. 2013 Dec;5(4):541-2
pubmed: 24454995
Rev Panam Salud Publica. 2016 Dec;40(6):455-461
pubmed: 28718495
Sex Transm Infect. 2017 Dec;93(S4):S3-S15
pubmed: 28747410
J Int AIDS Soc. 2017 Jun 28;20(1):21579
pubmed: 28691435

Auteurs

Laura Fernàndez-López (L)

Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Badalona, Spain. lflopez@iconcologia.net.
Institute for Health Science Research Germans Trias I Pujol (IGTP), Badalona, Spain. lflopez@iconcologia.net.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. lflopez@iconcologia.net.

Juliana Reyes-Urueña (J)

Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Badalona, Spain.
Institute for Health Science Research Germans Trias I Pujol (IGTP), Badalona, Spain.

Laia Egea (L)

Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Badalona, Spain.
School of Mathematics, Statistics and Operations Research, Victoria University of Wellington, Wellington, New Zealand.

Andrii Chernyshev (A)

ALLIANCE.GLOBAL, Public Organization, Kiev, Ukraine.

Inga Upmace (I)

NGO "Baltic HIV Association", Riga, Latvia.

Mitja Ćosić (M)

Association Legebitra, Ljubljana, Slovenia.

William Mejías (W)

Gais Positius, Barcelona, Spain.

Victoria González (V)

Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Badalona, Spain.
Institute for Health Science Research Germans Trias I Pujol (IGTP), Badalona, Spain.
Microbiology Department, Laboratori Clínic Metropolitana Nord. Hospital Universitari Germans Trias I Pujol, Badalona, Spain.

Karel Blondeel (K)

Department of Sexual and Reproductive Health and Research (SRH), including UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), World Health Organization, Geneva, Switzerland.
Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.

Soe Soe Thwin (SS)

Department of Sexual and Reproductive Health and Research (SRH), including UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), World Health Organization, Geneva, Switzerland.

Lorenzo Gios (L)

Epidemiology Unit - Division of Infectious Diseases, Department of Medicine, Verona University Hospital, Verona, Italy.

Massimo Mirandola (M)

Epidemiology Unit - Division of Infectious Diseases, Department of Medicine, Verona University Hospital, Verona, Italy.
School of Sport and Health Sciences, University of Brighton, Brighton, UK.

Rosanna Peeling (R)

International Diagnostics Centre, London School of Hygiene & Tropical Medicine, London, UK.

James Kiarie (J)

Department of Sexual and Reproductive Health and Research (SRH), including UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), World Health Organization, Geneva, Switzerland.

Jordi Casabona (J)

Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Badalona, Spain.
Institute for Health Science Research Germans Trias I Pujol (IGTP), Badalona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Igor Toskin (I)

Department of Sexual and Reproductive Health and Research (SRH), including UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), World Health Organization, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH